Methylprednisolone pulse therapy: An alternative management of severe COVID-19

Sauñe P.M.; Bryce-Alberti M.; Portmann-Baracco A.S.; Accinelli R.A. · Respiratory Medicine Case Reports (2020) · DOI: 10.1016/j.rmcr.2020.101221

Resumen

We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asymptomatic disease, non-severe symptomatic disease, and severe respiratory inflammatory disease. The first two forms are dependent on viral response and a “cytokine storm” is responsible for the progression into severe disease. Glucocorticoids (GC) reduce inflammation by different mechanism depending of their concentration. Pulses lead to overall apoptosis of immune cells. Studies using pulse MP as treatment for SARS-CoV-1 showed clinical improvement and decreased incidence of ARDS compared with patients who received low dose steroid treatment. Inhibition of excessive inflammation through timely administration of GC in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS.

Instituciones: Universidad Peruana Cayetano Heredia; Universidad Privada San Juan Bautista